Baseline characteristic Total (90 FN episodes), No. (%) Intervention (45 FN episodes), No. (%) Control (45 FN episodes), No. (%) P value
Age, mean years ± SD 51.6 ± 15.6 15.6 ± 14.6 52.0 ± 16.7 0.894
Male 42 (46.7) 16 (35.6) 26 (57.8) 0.035
Weight, mean kg ± SD 57.76 ± 1.50 58.94 ± 1.94 60.57 ± 2.30 0.590
Cause of febrile neutropenia
Cytotoxic chemotherapy 67 (74.4) 34 (75.6) 33 (73.3) 1.000
During period of initial hematologic abnormalities diagnosis 20 (22.2) 10 (22.2) 10 (22.2) 1.000
Other causesa 3 (3.33) 1 (2.22) 2 (4.44) 1.000
Active hematologic cancer 72 (80) 34 (75.6) 38 (84.4) 0.496
Active solid cancer 8 (8.9) 4 (8.9) 4 (8.9) 0.496
MASCC score, median (IQR) 20 (17-21) 19 (13-21) 21 (19-21) 0.129
High risk of febrile neutropenia (MASCC<21) 45 (50) 25 (55.6) 20 (44.4) 0.292
Absolute neutrophil count, median cells/mm3 (IQR) 153.9 (19– 520) 184 (40-645) 77 (13-368) 0.198
Had history of febrile neutropenia 46 (51.1) 20 (44.4) 26 (57.8) 0.206
Recent exposed to antibiotic within past 3 months 50 (55.6) 25 (55.6) 25 (55.6) 1.000
Neutropenia duration, median days (IQR) 7 (4-14) 8 (4-14) 6 (4-10) 0.435
Infectious diseases specialist consultation 50 (55.6) 27 (60) 23 (51.1) 0.396
Time to administer antibiotic, median hours (IQR) 1 (0-4) 1.5 (0-4) 1 (0-4) 0.497
Microbiological data
Causative organism identified 49 (54.4) 26 (57.8) 23 (51.1) 0.525
Gram positive bacteria 12 (13.3) 7 (15.6) 5 (11.1) 0.774
Gram negative bacteria 39 (43.3) 20 (44.4) 19 (42.2) 0.761
ESBL-producing organisms 12 (13.3) 3 (6.7) 9 (20) 0.118
Carbapenem resistance organisms 5 (5.6) 4 (8.9) 1 (2.2) 0.361